
样式: 排序: IF: - GO 导出 标记为已读
-
Oropharyngeal Microbiota Clusters in Children with Asthma or Wheeze Associate with Allergy, Blood Transcriptomic Immune Pathways, and Exacerbation Risk. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-15 Mahmoud I Abdel-Aziz,Jonathan Thorsen,Simone Hashimoto,Susanne J H Vijverberg,Anne H Neerincx,Paul Brinkman,Wim van Aalderen,Jakob Stokholm,Morten Arendt Rasmussen,Michael Roggenbuck-Wedemeyer,Nadja H Vissing,Martin Steen Mortensen,Asker Daniel Brejnrod,Louise J Fleming,Clare S Murray,Stephen J Fowler,Urs Frey,Andrew Bush,Florian Singer,Gunilla Hedlin,Björn Nordlund,Dominick E Shaw,Kian Fan Chung,Ian
Rationale: Children with preschool wheezing or school-age asthma are reported to have airway microbial imbalances. Objectives: To identify clusters in children with asthma or wheezing using oropharyngeal microbiota profiles. Methods: Oropharyngeal swabs from the U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes) pediatric asthma or wheezing cohort were characterized
-
A Double-Blind, Randomised, Placebo-controlled Trial of Long-Term Doxycycline Therapy on Exacerbation Rate in Patients with Stable COPD. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-14 James P Allinson,Ben H Vlies,Simon E Brill,Martin Law,Girvan Burnside,Lydia J Finney,Luana Alves-Moreira,Gavin C Donaldson,Peter M A Calverley,Paul P Walker,Jadwiga A Wedzicha
RATIONALE COPD exacerbations are a major cause of morbidity and mortality and preventing them is a key treatment target. Long-term macrolide treatment is effective at reducing exacerbations but there is a paucity of evidence for other antibiotic classes. To assess whether 12-month use of doxycycline reduces exacerbation rate in people with COPD. METHODS People with moderate to very severe COPD and
-
Unraveling the Distal Lung Destruction in Emphysema. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-14 Irina Petrache
-
Revised Paradigm for Acute Pulmonary Embolism Prognostication and Treatment. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-14 David Jiménez,Victor Tapson,Roger D Yusen,Cecilia Becattini,Lisa Moores,Geoffrey D Barnes,Manuel Monreal,Stavros Konstantinides,Behnood Bikdeli
-
Inflating or Over-Inflation? New Evidence for Lung Injury at Birth. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-14 Indya M Davies,Graeme R Polglase
-
Assessing Regional Lung Perfusion Changes to Inhaled Pulmonary Vasodilators by Electrical Impedance Tomography. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-14 Stefano Cenci,Roberta De Santis Santiago,Edward A Bittner,Lorenzo Berra
-
Reply to: Renal Replacement Therapy in a World of Constraints: Lessons from the COVID-19 Pandemic. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-12 Armand Mekontso Dessap,Romain Arrestier,Pierre-Antoine Billiet
-
Renal Replacement Therapy in a World of Constraints: Lessons from the COVID-19 Pandemic. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-12 Stephane Gaudry,Khalil Chaïbi,Didier Dreyfuss
-
Icenticaftor, Novel Therapy for COPD: This Glass Is Half Full. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-12 Stephen I Rennard
-
Heterogeneous Treatment Effects of Extracorporeal CO2 Removal in Acute Hypoxemic Respiratory Failure. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-11 Ewan C Goligher,James J McNamee,Jose Dianti,Eddy Fan,Niall D Ferguson,Arthur S Slutsky,Daniel F McAuley
-
A New Treatment for COPD: Ensifentrine Moves Closer. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-11 Dave Singh
-
Causes of Death in Smokers: Implications for COPD Management Across Disease Severity. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-10 Jadwiga A Wedzicha
-
Age of Initiating Smoking: An Independent Predictor of COPD in Later Life. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-10 Donald P Tashkin
-
Pulmonary Hypertension in Myeloproliferative Neoplasms: New Insights and Unexplored Horizons. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-10 Orly Leiva,Brenda D Garcia,Gabriela Hobbs
-
Sleep Apnea Physiological Burdens and Cardiovascular Morbidity and Mortality. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-07 Gonzalo Labarca,Daniel Vena,Wen-Hsin Hu,Neda Esmaeili,Laura Gell,Hyung Chae Yang,Tsai-Yu Wang,Ludovico Mesineo,Luigi Taranto-Montemurro,Tamar Sofer,Robert G Barr,Katie L Stone,David P White,Andrew Wellman,Scott Sands,Susan Redline,Ali Azarbarzin
This article will be available on July 26, 2023.
-
Assessment of Preserved Ratio Impaired Spirometry (PRISm) Using Pre and Post Bronchodilator Spirometry in a Randomly-Sampled Symptomatic Cohort. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-06 Kate M A Magner,Mathew Cherian,G A Whitmore,Katherine L Vandemheen,Celine Bergeron,Andreanne Cote,Stephen K Field,Catherine Lemière,R Andrew McIvor,Shawn D Aaron
-
Prostaglandin I2 Therapy Promotes Treg Generation in Patients with Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-06 Allison E Norlander,Masako Abney,Jacqueline-Yvonne Cephus,Caroline E Roe,Jonathan M Irish,Nicholas J Shelburne,Dawn C Newcomb,Anna R Hemnes,R Stokes Peebles
-
Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-06 Fernando J Martinez,Gerard J Criner,Christian Gessner,Margret Jandl,Fernando Scherbovsky,Masaharu Shinkai,Thomas M Siler,Claus F Vogelmeier,Robert Voves,Jadwiga A Wedzicha,Christian Bartels,Ivan Bottoli,Stuart Byiers,Pamela Cardenas,Joerg H Eckert,Florian S Gutzwiller,Barbara Knorr,Mahavir Kothari,Rutvick Parlikar,Ana-Maria Tanase,Frits M E Franssen
RATIONALE CF transmembrane conductance regulator (CFTR) dysfunction is associated with mucus accumulation and worsening COPD symptoms. This Phase 2b dose-finding study compared a CFTR potentiator, icenticaftor (QBW251), with placebo in patients with COPD and chronic bronchitis. METHODS COPD patients on triple therapy for at least three months were randomized to six treatment arms (icenticaftor 450
-
Distinct Genomic Landscape of Lung Adenocarcinoma from Household Use of Smoky Coal. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-05 Tongwu Zhang,Phuc H Hoang,Jason Y Y Wong,Kaiyun Yang,Kexin Chen,Maria Pik Wong,Roel C H Vermeulen,Yunchao Huang,Stephen J Chanock,Nathaniel Rothman,Qing Lan,Maria Teresa Landi,
-
A Single-Cell Atlas of Small Airway Disease in Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-05 Steven Booth,Aileen Hsieh,Leila Mostaco-Guidolin,Hyun-Kyoung Koo,Keith Wu,Fatemeh Aminazadeh,Chen Xi Yang,Daniela Quail,Yuhong Wei,Joel D Cooper,Peter D Paré,James C Hogg,Dragoş M Vasilescu,Tillie-Louise Hackett
RATIONALE Emerging data demonstrate that the smallest conducting airways, terminal bronchioles are the early site of tissue destruction in COPD and are reduced up to 41% by the time someone is diagnosed with mild (GOLD 1) COPD. OBJECTIVES To develop a single-cell atlas that describes the structural, cellular and extracellular matrix alterations underlying terminal bronchiole loss in COPD. METHODS This
-
Let Us Play the Blues: The Use of Methylene Blue for IR Localization of Source of Hemoptysis Under Bronchoscopic Guidance. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-30 Prince Ntiamoah,Christopher Yurosko,Ihab Haddadin,Thomas R Gildea
-
Reply to Jimenez and Hyzy, and to Le Stang and Dres. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-30 Annemijn Jonkman,Laurent Brochard
-
Electrical Impedance Tomography and Optimal PEEP: Uncovering Latent Heterogeneity of Treatment Effect. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-30 Jose Victor Jimenez,Robert C Hyzy
-
Finding Facts in PASC: Clinical, Radiographic and Histopathologic Markers of Disease. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-30 Chiagozie I Pickens,Benjamin D Singer
-
External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real World Data Sources. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-29 Aparna C Swaminathan,Laurie D Snyder,Hwanhee Hong,Susanna R Stevens,Alexander S Long,Eric Yanchenko,Ying Qiu,Rong Liu,Hongtao Zhang,Aryeh Fischer,Leah Burns,Lisa M Wruck,Scott M Palmer
RATIONALE Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease for which novel therapies are needed. External controls (ECs) could enhance IPF trial efficiency, though the direct comparability of ECs to concurrent controls is unknown. OBJECTIVES To develop IPF ECs by fit for purpose data standards to historical randomized clinical trial (RCT), multicenter registry (Pulmonary Fibrosis Foundation
-
Unmet Diagnostic and Therapeutic Opportunities for COPD in Low- and Middle-Income Countries. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-27 Katia Eh Florman,Trishul Siddharthan,Suzanne L Pollard,Patricia Alupo,Julie A Barber,Ram K Chandyo,Oscar Flores-Flores,Bruce Kirenga,Renata Gonçalves Mendes,J Jaime Miranda,Sakshi Mohan,Federico Ricciardi,Natalie A Rykiel,Arun K Sharma,Adaeze C Wosu,William Checkley,John R Hurst,
RATIONALE Chronic obstructive pulmonary disease (COPD) is a prevalent and burdensome condition in low- and middle-income countries (LMICs). Challenges to better care include more effective diagnosis, and access to affordable interventions. There are no previous reports describing therapeutic needs in LMIC populations with COPD identified through screening. OBJECTIVE To describe unmet therapeutic need
-
Thiamine for Renal Protection in Septic Shock (TRPSS): A Randomized, Placebo-Controlled Trial. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-26 Ari Moskowitz,Katherine M Berg,Anne V Grossestreuer,Lakshman Balaji,Xiaowen Liu,Michael N Cocchi,Maureen Chase,Michelle Ng Gong,Jonathan Gong,Samir M Parikh,Long Ngo,Noa Berlin,Michael W Donnino
RATIONALE Kidney injury is common and associated with worse outcomes in patient with septic shock. Mitochondrial resuscitation with thiamine (vitamin B1) may attenuate septic kidney injury. OBJECTIVES To assess whether thiamine supplementation attenuates kidney injury in septic shock. METHODS The Thiamine for Renal Protection in Septic Shock (TRPSS) trial was a multicenter, randomized, placebo-controlled
-
Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials). Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-26 Antonio Anzueto,Igor Z Barjaktarevic,Thomas M Siler,Tara Rheault,Thomas Bengtsson,Kathleen Rickard,Frank Sciurba,
RATIONALE Ensifentrine is a novel, selective, dual phosphodiesterase (PDE)3 and PDE4 inhibitor with bronchodilator and anti-inflammatory effects. Replicate Phase 3 trials of nebulized ensifentrine were conducted (ENHANCE-1 and ENHANCE-2) to assess these effects in patients with COPD. OBJECTIVES To evaluate the efficacy of ensifentrine compared to placebo on lung function, symptoms, quality of life
-
Deep Learning Assessment of Progression of Emphysema and Fibrotic Interstitial Lung Abnormality. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-26 Samuel Y Ash,Bina Choi,Andrea Oh,David A Lynch,Stephen M Humphries,
RATIONALE While studies have evaluated emphysema and fibrotic interstitial lung abnormality (ILA) individually, less is known about their combined progression. OBJECTIVES To define clinically meaningful progression of fibrotic ILA in smokers without interstitial lung disease and evaluate the effects of fibrosis and emphysema progression on mortality. METHODS Emphysema and pulmonary fibrosis were assessed
-
Leveraging Omics to Predict COPD Exacerbations: The "Immunome". Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-23 Francesca Polverino,Ravi Kalhan
-
Inclusivity in Research Matters: Variants in PVT1 Specific to People of African Descent Are Associated with Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-22 Lori Garman,Nathan Pezant,Bryan A Dawkins,Astrid Rasmussen,Albert M Levin,Benjamin A Rybicki,Michael C Iannuzzi,Harini Bagavant,Umesh S Deshmukh,Courtney G Montgomery
-
The Potential Role of Gastric Microbiology in Respiratory Disease. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-22 Chris Ward,Hafez Al Momani,Melissa J McDonnell,Desmond M Murphy,Laura Walsh,John Mac Sharry,Mike Griffin,Ian A Forrest,Rhys Jones,Amaran Krishnan,Jeffrey Pearson,Robert M Rutherford
-
Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-22 Klaus F Rabe,Stephen Rennard,Fernando J Martinez,Bartolome R Celli,Dave Singh,Alberto Papi,Mona Bafadhel,Jigna Heble,Amr Radwan,Xavier Soler,Juby A Jacob Nara,Yamo Deniz,Paul J Rowe
Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous, progressive inflammatory airway disease associated with significant impact on patients' lives, including morbidity and mortality, and significant health-care related costs. Current pharmacologic strategies, including first- and second-line therapies such as long-acting β2-agonists, long-acting muscarinic antagonists, inhaled
-
Reply to: The Potential Role of Gastric Microbiology in Respiratory Disease. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-22 Micheál Mac Aogáin,Jayanth Kumar Narayana,Sanjay H Chotirmall
-
Illuminating the Importance of Pulmonary Arterial Compliance in Pulmonary Hypertension. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-22 Jason Weatherald,Umberto Zanini,Marc Humbert
-
Better Survival with Less Morbidity in Extremely Preterm Infants: Attacking the Heart of the Matter. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-22 Nimish V Subhedar,Benjamin Frank,Steven H Abman
-
Viral-associated Pulmonary Aspergillosis: Have We Finally Overcome the Debate of Colonization Versus Infection? Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-22 Werner C Albrich,Frédéric Lamoth
-
Childhood Cigarette Smoking and Risk of COPD in Older U.S. Adults. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-22 James D Sargent,Michael Halenar,Alexander W Steinberg,Jenny Ozga,Zhiqun Tang,Cassandra A Stanton,Laura M Paulin
RATIONALE It is not certain the extent to which childhood smoking adds COPD risk independent of lifetime cigarette exposure. OBJECTIVES We examined the association between age started smoking cigarettes regularly, current smoking status, smoking history, and risk of COPD. METHODS Cross-sectional survey of U.S. adults ≥40y in the 2020 National Health Interview Survey. Respondents who were ever cigarette
-
Lung Cancer Risk and Delivering on The Promise of the Genomic Era. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-21 Douglas Arenberg
-
Introducing the Pulmonary Hypertension Thematic Series. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-21 Bradley A Maron
-
Upward Diaphragm Motion on Four-Dimensional Computed Tomography in Severe Diaphragm Weakness. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-20 Ken Tonai,Shinshu Katayama,Atsuko Shono,Shin Nunomiya
-
Green Pleural Effusion Secondary to Eosinophilic Autofluorescence. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-20 Adam Austin,Evan Asher,Jacquelyn A Knapik,Cesar Trillo-Alvarez,Hiren J Mehta
-
Consequences of Using Post- or Pre-Bronchodilator Reference Values in Interpreting Spirometry. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-20 Andrei Malinovschi,Xingwu Zhou,Anders Andersson,Helena Backman,Björn Bake,Anders Blomberg,Kenneth Caidahl,Maria J Eriksson,Jonas Eriksson Ström,Viktor Hamrefors,Ola Hjelmgren,Christer Janson,Reza Karimi,David Kylhammar,Anne Lindberg,Eva Lindberg,Per Liv,Anna-Carin Olin,Adel Shalabi,C Magnus Sköld,Johan Sundström,Hanan Tanash,Kjell Torén,Per Wollmer,Suneela Zaigham,Carl Johan Östgren,Jan E Engvall
RATIONALE Post-bronchodilator (BD) spirometry is used for diagnosis of chronic obstructive pulmonary disease (COPD). However, pre-BD reference values are used for spirometry interpretation. OBJECTIVES To compare the resulting prevalence rates of abnormal spirometry and study the consequences of using pre- or post-BD reference values generated within the Swedish CArdioPulmonary bioImage Study (SCAPIS)
-
Gas gangrene after thoracic drainage for empyema with tension pneumothorax. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-20 Yusuke Saeki,Yoshihiro Moriyama,Yuichi Araki,Atsushi Oda,Kojiro Nakaoka,Masaharu Inagaki
-
Pulmonary Artery Pseudoaneurysm as a Complication of Transbronchial Lung Cryobiopsy. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-20 Hiroki Ohta,Hideaki Yamakawa,Tamiko Takemura,Hidekazu Matsushima
-
FEV1/FVC Severity Stages for Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-20 Surya P Bhatt,Arie Nakhmani,Spyridon Fortis,Matthew J Strand,Edwin K Silverman,Frank C Sciurba,Sandeep Bodduluri
RATIONALE The diagnosis of COPD is based on low ratio of the forced expiratory volume in one second to the forced vital capacity (FEV1/FVC) but its severity is classified using percentage predicted FEV1 (ppFEV1). OBJECTIVE To test a new severity classification scheme for COPD using FEV1/FVC, a more robust measure of airflow obstruction than ppFEV1. METHODS In COPDGene (n=10,132), the severity of airflow
-
Enhancing the Efficacy of Mesenchymal Stromal Cells in COVID-19-related Acute Respiratory Distress Syndrome. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-15 Haibo Zhang,Arthur S Slutsky
-
ARDS Mediates the Association Between Early Plasma sRAGE Concentrations and Mortality in Sepsis. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-15 Tiffanie K Jones,John P Reilly,Brian J Anderson,Todd A Miano,Thomas G Dunn,Alexandra P Turner,Roseline S Agyekum,Rui Feng,Caroline A G Ittner,Michael G S Shashaty,Nuala J Meyer
-
Reply to: OSA with High Pulse Wave Amplitude Drops Index: A Specific Phenotype for Cardiovascular Benefit from CPAP? Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-15 Geoffroy Solelhac,Manuel Sánchez-de-la-Torre,Margaux Blanchard,Ferran Barbé,Frédéric Gagnadoux,Raphael Heinzer
-
OSA with High Pulse Wave Amplitude Drops Index: A Specific Phenotype for Cardiovascular Benefit from CPAP? Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-15 Yating Chen,Jingcun Wang,Shenyu Wen,Donghao Wang,Qiming Gan,Yiqi Lin,Jianxiong Lai,Haojie Zhang,Yanyan Zhou,Dongxing Zhao
-
αvβ6 Integrin Positron Emission Tomography of Lung Fibrosis in Idiopathic Pulmonary Fibrosis and Long COVID-19. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-15 Richard H Kimura,Husham Sharifi,Bin Shen,Gerald J Berry,H Henry Guo
-
Clinical, Imaging, and Histopathological Features of Pulmonary Sequelae Following Mild COVID-19. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-14 Daniel Gagiannis,Carsten Hackenbroch,Wilhelm Bloch,Fabian Zech,Frank Kirchhoff,Sonja Djudjaj,Saskia von Stillfried,Roman Bülow,Peter Boor,Konrad Steinestel
-
Reply to: Understanding the Pathophysiological and Clinical Changes in Lung Injury Models. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-14 Serena Brusatori,Carmelo Zinnato,Tommaso Pozzi,Luigi Camporota,John J Marini,Luciano Gattinoni
-
Understanding the Pathophysiological and Clinical Changes in Lung Injury Models. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-14 Ajay Kumar Jha
-
Hereditary Hemorrhagic Telangiectasia with Diffuse Bronchopulmonary Arteriovenous Malformations. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-14 Masayuki Nakajima,Yuko Morishima,Kensaku Mori,Kazufumi Yoshida,Kenya Kuramoto,Masashi Matsuyama,Takumi Kiwamoto,Yosuke Matsuno,Nobuyuki Hizawa
-
Use of CAPTURE to Identify Individuals Who May or May Not Require Treatment for COPD. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-06-14 Yun Li,Fuqiang Wen,Qianli Ma,Rongchang Chen,Yongchang Sun,Tiantian Liu,Chenjuan Gu,Shuling Hu,Jie Song,Chris Compton,Jinping Zheng,Nanshan Zhong,Paul Jones
RATIONALE The COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) tool was developed to identify patients with undiagnosed COPD with FEV1 <60% predicted or risk of exacerbation as treatment criteria. OBJECTIVES To test the ability of CAPTURE to identify patients requiring treatment because of symptoms or risk of exacerbation or hospitalization
-
Reply to Butler et al. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-15 Mona Eskandari,Jason H T Bates
-
Julius Comroe Is Right: Positive and Negative Pressure Ventilation Are the Same. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-15 James P Butler,Robert B Banzett,Stephen H Loring
-
Finding the Right Biological: Eosinophil Subset Differences in Asthma and Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-15 Christine M Freeman,Jeffrey L Curtis,Annette T Hastie
-
Lung Function as a Biomarker of Health: An Old Concept Rediscovered. Am. J. Respir. Crit. Care Med. (IF 24.7) Pub Date : 2023-07-15 Myrtha E Reyna,Marc-Antoine Bedard,Padmaja Subbarao